A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Drug: Giredestrant
61 locations incl. Daphne
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT06065748·Phase 3·Recruiting